- Home
- XGN vs CUE Comparison
XGN vs CUE Comparison
Compare XGN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- CUE
- Stock Information
- Founded
- XGN 2002
- CUE 2014
- Country
- XGN United States
- CUE United States
- Employees
- XGN N/A
- CUE N/A
- Industry
- XGN Medical Specialities
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- CUE Health Care
- Exchange
- XGN Nasdaq
- CUE Nasdaq
- Market Cap
- XGN 72.3M
- CUE 77.3M
- IPO Year
- XGN 2019
- CUE 2018
- Fundamental
- Price
- XGN $5.65
- CUE $1.15
- Analyst Decision
- XGN Buy
- CUE Strong Buy
- Analyst Count
- XGN 1
- CUE 5
- Target Price
- XGN $7.00
- CUE $5.00
- AVG Volume (30 Days)
- XGN 189.6K
- CUE 378.2K
- Earning Date
- XGN 11-12-2024
- CUE 11-14-2024
- Dividend Yield
- XGN N/A
- CUE N/A
- EPS Growth
- XGN N/A
- CUE N/A
- EPS
- XGN N/A
- CUE N/A
- Revenue
- XGN $55,751,000.00
- CUE $9,532,000.00
- Revenue This Year
- XGN $6.74
- CUE $105.39
- Revenue Next Year
- XGN $17.32
- CUE N/A
- P/E Ratio
- XGN N/A
- CUE N/A
- Revenue Growth
- XGN 8.00
- CUE 149.53
- 52 Week Low
- XGN $1.30
- CUE $0.45
- 52 Week High
- XGN $6.22
- CUE $3.20
- Technical
- Relative Strength Index (RSI)
- XGN 74.82
- CUE 45.52
- Support Level
- XGN $5.60
- CUE $0.92
- Resistance Level
- XGN $6.22
- CUE $1.09
- Average True Range (ATR)
- XGN 0.48
- CUE 0.11
- MACD
- XGN 0.13
- CUE 0.00
- Stochastic Oscillator
- XGN 88.00
- CUE 45.71
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.